Background:
Advanced ovarian cancer is a highly dangerous disease, and many patients lose their lives due to limited treatment effectiveness. Previous studies have shown that current immunotherapy (e.g., PD-1 inhibitors) has poor results in ovarian cancer. The research team discovered that adding "heated abdominal chemotherapy" (called HIPEC, which uses a heated drug solution to wash the abdomen) to standard chemotherapy helps patients better control tumors. Recent lab studies also found that HIPEC not only reduces "harmful cells" around tumors that block drug effectiveness but also makes immunotherapy drugs work better. Animal experiments further confirmed that combining HIPEC with immunotherapy improves outcomes. Therefore, the investigators aim to test a key question: Can HIPEC help immunotherapy drugs work more effectively in humans?
Study Details:
The study will conduct a small two-phase trial, planning to enroll 30 patients with advanced ovarian cancer (Stage IIIc-IVA). All participants will receive standard chemotherapy (paclitaxel + platinum drugs) combined with HIPEC and an immunotherapy drug (tislelizumab, a PD-1 inhibitor). The main goal is to check whether tumors are completely removed after surgery. Investigators will also track how long tumors stay under control, overall survival time, treatment safety, and use blood and tumor tissue tests to find biomarkers that predict treatment response.
Why This Matters:
The study hopes to identify a safe method to enhance immunotherapy effectiveness and offer improved outcomes for advanced ovarian cancer patients.
Diagnosed with FIGO stage IIIC-IVA high-grade serous ovarian adenocarcinoma (histologically confirmed).
Aged 18-70 years.
Life expectancy ≥12 months.
CT Suidan score ≥7 and Fagotti score ≥8 (assessed by two independent gynecologic oncologists via laparoscopic evaluation).
Partial or complete bowel obstruction.
Intestinal fistula of any grade.
Hydronephrosis unrelieved by ureteral stenting.
History of organ transplantation.
Single group
ICI-HIPET
DrugPatients received the following interventions: On Day 0, intravenous administration of tislelizumab (an anti-PD-1 immune checkpoint inhibitor) was initiated within 3 hours post-HIPEC. Tumor tissue samples were collected before HIPEC, at 30 minutes, 60 minutes, and 90 minutes (end of HIPEC). Serum samples were collected pre- and post-HIPEC. On Day 1, additional serum samples were collected 24 hours after HIPEC-ICI completion. From Days 2-3, patients underwent paclitaxel + carboplatin chemotherapy, with serum sampling repeated at 48 hours post-HIPEC-ICI. On Days 21 and 42, the second and third cycles of neoadjuvant chemotherapy (tislelizumab + paclitaxel + carboplatin) were administered intravenously.
R0 Resection Rate
R0 resection rate refers to the proportion of patients achieving complete macroscopic tumor removal (no visible residual disease) during interval debulking surgery after three cycles of neoadjuvant chemotherapy. This is determined by the surgeon's intraoperative assessment of the pelvic and abdominal cavities for any gross residual lesions.
Rate of progression-free survival
The 1-year, 2-year, and median progression-free survival (PFS) rates of patients were calculated.
Rate of overall survival
The 1-year, 2-year overall survival (OS) rates and median OS of patients were calculated.
Pathological response rate
Independently assessed by pathologists, defined as the absence of microscopic residual tumor in all specimens obtained during interval debulking surgery. Incidence of chemotherapy response score 3 (CRS3): Following three cycles of neoadjuvant therapy, patients underwent surgical debulking via laparotomy. The omental tissue was evaluated using the chemotherapy response score (CRS) system to determine the rate of CRS3 (indicating complete or near-complete pathological response).
Radiological Response Rate
Independently assessed by radiologists using baseline CT or MRI (prior to neoadjuvant therapy) as reference. Tumor changes were evaluated after three cycles of neoadjuvant therapy, categorized as follows: Complete Response (CR): Disappearance of all target lesions, except for nodal disease. All target nodes must shrink to normal size (short axis \<10 mm). All lesions must be assessed. Partial Response (PR): ≥30% reduction in the sum of diameters of all measurable target lesions compared to baseline. Nodal lesions are measured by short axis, while non-nodal lesions use the longest diameter. All lesions must be assessed. Progressive Disease (PD): At least a 20% increase in the sum of diameters relative to the smallest value recorded during the study (or baseline if no decrease was observed), plus an absolute increase of ≥5 mm. Appearance of new lesions also qualifies as PD. Stable Disease (SD): Neither sufficient shrinkage to qualify as PR nor sufficient increase to qualify as PD
Adverse Event (AE) Incidence
Adverse events occurring during the study were evaluated and recorded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0. Data included the number of patients (incidence), type of events, and severity (graded from Grade 1 to Grade 5 based on CTCAE criteria).
Click on the lead sponsor to view all of their trials.
Jing Li
Lead sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Sponsor institution
This trial is not recruiting at the moment. You can still explore other options:
